Avalere Health

Overview

Avalere Health is a health-policy-led market access and commercialization partner for life-sciences teams. The current public buyer read is broader than the historical Washington, DC policy-consulting frame: Avalere combines policy analysis, payer/access strategy, HEOR and evidence planning, medical communications, and marketing support under one global organization.

For a biopharma launch team, the useful read is where Avalere is strongest against the operating work a manufacturer must buy. Market access consultancies should be compared by payer insight, pricing/contracting strategy, HEOR depth, payer engagement, policy depth, and launch execution support. Avalere’s strongest public fit is policy-sensitive access work where CMS implementation, IRA exposure, Medicare, Medicaid, 340B, or evidence strategy materially changes launch planning.

Market Access Capability Model

The framework below standardizes how Rx Almanac evaluates market-access-consulting capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Avalere Health is evaluated as health-policy-led market access and commercialization partner for life-sciences teams.

Capability	Buyer should compare	Avalere Health readout
Payer landscape and access strategy	Payer segmentation, formulary expectations, coverage barriers, benefit design, and access scenario planning.	Core access strategy. Avalere is strongest when payer strategy needs to be interpreted through active policy and regulatory change, not just static coverage research.
Pricing, contracting, and GTN strategy	WAC strategy, rebate design, contracting scenarios, GTN forecasting, channel economics, and net-price risk.	Core access strategy. Best suited for IRA, Medicare, Medicaid, 340B, and policy-driven pricing or contracting questions where access strategy and statutory exposure need to be reconciled.
HEOR, value dossiers, and evidence planning	Budget impact, cost-effectiveness, AMCP dossier, evidence gaps, PRO endpoints, and value story.	Core evidence work. Evidence planning is part of Avalere’s Medical and Advisory model, with real-world evidence and value demonstration tied to access and launch decisions.
Payer engagement and message testing	Ad boards, mock P&T, payer research, message testing, objection handling, and stakeholder mapping.	Documented in profile. Use RFP diligence to confirm which payer inputs are primary research, standing panels, claims/formulary data, or consultant judgment for the specific engagement.
Policy, IRA, Medicaid, and channel strategy	IRA, Medicaid, 340B, Medicare, specialty channel, distribution, and policy-risk implications.	Core / differentiated. This is the center of gravity: Avalere’s public footprint is strongest around CMS, Medicare, Medicaid, IRA, federal/state policy, and reimbursement implications.
Launch sequencing and execution support	Cross-functional launch planning, access playbooks, field tools, governance, and implementation support.	Documented in profile. The integrated Advisory, Medical, and Marketing model is most useful when launch planning must connect evidence, access, policy, medical, and brand execution.

Buyer Fit

• Strongest fit: Use Avalere when policy, reimbursement, value evidence, and access strategy need to be resolved together before launch or major label/lifecycle events.
• Therapy and product fit: Public signals point to specialty, biologics, and small-molecule products, with recent emphasis on oncology, immunology, rare disease, diabetes, and other policy-sensitive categories.
• Commercial fit: Pricing is Custom/RFP, so assume an RFP-led scope with senior-team access, deliverables, evidence inputs, decision rights, and implementation handoffs defined in the statement of work.
• Profile signal: Avalere is more differentiated for policy-sensitive access and evidence strategy than for commodity payer research alone.
• Network diligence: Confirm which practice owns the workstream, how Advisory, Medical, and Marketing teams will coordinate, and what outputs can be used directly by access, medical, brand, field, and patient-services teams.

Differentiators

• Policy-first access strategy: Avalere is one of the clearer public examples of a market-access consultant that starts from CMS, Medicare, Medicaid, IRA, 340B, and federal/state policy implications.
• Integrated Advisory, Medical, and Marketing model: The public rebrand consolidated market access, medical, and marketing capabilities into one operating model rather than separate boutique relationships.
• Evidence and access connection: The real-world evidence and HEOR lane is most valuable when evidence strategy must support payer, policy, and launch decisions rather than sit as a standalone analytics workstream.
• Market Access Marketing: Avalere has public leadership and service-line signals around connecting policy/access insight with brand, media, and commercialization execution.
• Global expansion: The 2026 Japan launch adds a Tokyo-based integrated advisory, medical, and marketing offering for biopharma companies operating in a complex access and launch environment.

RFP Questions

• Which payer and policy inputs are primary research, standing panels, claims/formulary data, public-policy analysis, or consultant judgment?
• How will pricing, contracting, evidence, and patient-services recommendations be reconciled into one launch plan?
• Which deliverables can be used directly by account teams, field reimbursement, hub vendors, brand teams, and medical affairs?
• Which party will staff the engagement across Advisory, Medical, and Marketing, and how often will senior policy or HEOR leads be directly involved?
• What assumptions are most sensitive to CMS, IRA, Medicaid, 340B, or state-policy changes, and how will the team update the model if policy shifts during the engagement?

Recent Activity

• May 2026: Expanded into Japan with a Tokyo office led by Junji Yokokawa and a full-service Advisory, Medical, and Marketing offering.
• December 2025: Sarah Hall, formerly of FCB Health New York, joined as President of US Marketing.
• December 2025: Matt Kazan returned as Senior Vice President, Policy, and Laura Housman was elevated to Chief Public Health Officer.
• February 2025: Launched the Every Patient Possible public commitment, reinforcing the unified Avalere Health identity.
• December 2024: Amar Urhekar was announced as CEO after serving as chief operating officer.